HANSOH PHARMA (03692.HK): Class 1 Innovative Drug HS-20197 for Injection Receives Clinical Trial Approval Notice, Intended for Advanced Solid Tumours
- The drug is a Class 1 innovative drug independently developed by the Group.
- The drug clinical trial approval notice was issued on 11 September 2026.
NewTimeSpace News: On 16 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692.HK) announced that on 11 September 2026, HS-20197 for injection, a Class 1 innovative drug independently developed by the Group, obtained a drug clinical trial approval notice issued by the National Medical Products Administration (NMPA) of the PRC, for the conduct of clinical trials in "advanced solid tumours".
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- HANSOH PHARMA (03692.HK): Signs ADC Strategic Collaboration and Licence with Roche; US$400mn Upfront, Over US$15bn Milestones
- HANSOH PHARMA (03692.HK): Refiles EU Marketing Application for Aumseqa
- Hansoh(03692.HK): EU revokes Aumolertinib approval, EMA resubmission planned
